Q0180
Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
- Effective Date: 1998-04-01
- Medicare Coverage Status: Special coverage instructions apply
- BETOS Classification: Chemotherapy
Medicare has not assigned a fee schedule for this code
Q0177
Q0181 